New research reveals that individuals who come off blockbuster GLP-1 drugs like Mounjaro or Wegovy tend to recover lost weight much more quickly than those who halt traditional lifestyle regimens.
Findings released in a prominent medical journal shows that while obese individuals frequently drop about a fifth of their total mass while on the medication, the mass returns at an average rate of 0.8 kg per month after stopping.
"Users buying these treatments must be aware of the risk of rapid weight regain when the medication concludes," stated researcher Dr. Susan Jebb.
This pace of recovery suggests a return to pre-treatment mass in about one and a half years.
Weighing Approaches
The research, which examined dozens of trials involving over 9,000 of participants, contrasted the results of the injectable medications with conventional dieting.
The team emphasize that people who shed pounds through dieting usually see a less rapid weight regain—perhaps 100 grams monthly—after stopping.
The Reason for the Quick Rebound
Doctors propose the mechanism of the drugs is key to understanding the amplified rebound.
These medications copy a body's own chemical called GLP-1, which moderates hunger.
"Artificially providing the hormone levels several times higher than normal may cause the system to generate a reduced amount of its endogenous hormone, and may also reduce sensitivity to its actions," said Dr. Adam Collins, a nutrition researcher.
"Stopping of this hormone supplement results in appetite is uncontrolled, making overeating much more probable."
A Chronic Disease?
Medical guidelines recommend the jabs for individuals with obesity-related health risks, accompanied by recommended lifestyle changes.
Professionals argue that, due to the significant potential of relapse, the therapy should be considered long-term.
This view is reinforced by drug manufacturers, who say that the findings "underscore the persistent nature of excess weight," akin to managing diseases like diabetes.
Patient Experiences
People who have come off the jabs describe a sudden resurgence of appetite.
"It felt as if a switch flipping and you become ravenous," described one woman.
This challenge is compounded if users have not adopted permanent dietary or behavioural changes during therapy.
Significant Use
Recent estimates suggest that millions of adults in the UK have tried weight-loss jabs in the last 12 months, with demand remaining high.
- Adoption is more common among women than men.
- The middle-aged age group shows the highest level of interest.
- A large proportion obtain the medications through private prescriptions rather than public health services.
Ultimately, researchers stress that while these medications are potent tools for weight loss, they are not a magic fix and long-term success hinges on ongoing behavioural support.
